Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study.
Duration of response
Immune checkpoint inhibitors
Metastatic Merkel cell carcinoma
Rechallenge of immune checkpoint inhibitors
Treatment cessation
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
30
09
2020
accepted:
23
03
2021
pubmed:
20
4
2021
medline:
16
10
2021
entrez:
19
4
2021
Statut:
ppublish
Résumé
Immune checkpoint inhibitors (ICI) have led to a prolongation of progression-free and overall survival in patients with metastatic Merkel cell carcinoma (MCC). However, immune-mediated adverse events due to ICI therapy are common and often lead to treatment discontinuation. The response duration after cessation of ICI treatment is unknown. Hence, this study aimed to investigate the time to relapse after discontinuation of ICI in MCC patients. We analyzed 20 patients with metastatic MCC who have been retrospectively enrolled at eleven skin cancer centers in Germany. These patients have received ICI therapy and showed as best overall response (BOR) at least a stable disease (SD) upon ICI therapy. All patients have discontinued ICI therapy for other reasons than disease progression. Data on treatment duration, tumor response, treatment cessation, response durability, and tumor relapse were recorded. Overall, 12 of 20 patients (60%) with MCC relapsed after discontinuation of ICI. The median response durability was 10.0 months. Complete response (CR) as BOR to ICI-treatment was observed in six patients, partial response (PR) in eleven, and SD in three patients. Disease progression was less frequent in patients with CR (2/6 patients relapsed) as compared to patients with PR (7/11) and SD (3/3), albeit the effect of initial BOR on the response durability was below statistical significance. The median duration of ICI therapy was 10.0 months. Our results did not show a correlation between treatment duration and the risk of relapse after treatment withdrawal. Major reasons for discontinuation of ICI therapy were CR (20%), adverse events (35%), fatigue (20%), or patient decision (25%). Discontinuation of ICI due to adverse events resulted in progressive disease (PD) in 71% of patients regardless of the initial response. A re-induction of ICI was initiated in 8 patients upon tumor progression. We observed a renewed tumor response in 4 of these 8 patients. Notably, all 4 patients showed an initial BOR of at least PR. Our results from this contemporary cohort of patients with metastatic MCC indicate that MCC patients are at higher risk of relapse after discontinuation of ICI as compared to melanoma patients. Notably, the risk of disease progression after discontinuation of ICI treatment is lower in patients with initial CR (33%) as compared to patients with initial PR (66%) or SD (100%). Upon tumor progression, re-induction of ICI is a feasible option. Our data suggest that the BOR to initial ICI therapy might be a potential predictive clinical marker for a successful re-induction.
Sections du résumé
BACKGROUND
BACKGROUND
Immune checkpoint inhibitors (ICI) have led to a prolongation of progression-free and overall survival in patients with metastatic Merkel cell carcinoma (MCC). However, immune-mediated adverse events due to ICI therapy are common and often lead to treatment discontinuation. The response duration after cessation of ICI treatment is unknown. Hence, this study aimed to investigate the time to relapse after discontinuation of ICI in MCC patients.
METHODS
METHODS
We analyzed 20 patients with metastatic MCC who have been retrospectively enrolled at eleven skin cancer centers in Germany. These patients have received ICI therapy and showed as best overall response (BOR) at least a stable disease (SD) upon ICI therapy. All patients have discontinued ICI therapy for other reasons than disease progression. Data on treatment duration, tumor response, treatment cessation, response durability, and tumor relapse were recorded.
RESULTS
RESULTS
Overall, 12 of 20 patients (60%) with MCC relapsed after discontinuation of ICI. The median response durability was 10.0 months. Complete response (CR) as BOR to ICI-treatment was observed in six patients, partial response (PR) in eleven, and SD in three patients. Disease progression was less frequent in patients with CR (2/6 patients relapsed) as compared to patients with PR (7/11) and SD (3/3), albeit the effect of initial BOR on the response durability was below statistical significance. The median duration of ICI therapy was 10.0 months. Our results did not show a correlation between treatment duration and the risk of relapse after treatment withdrawal. Major reasons for discontinuation of ICI therapy were CR (20%), adverse events (35%), fatigue (20%), or patient decision (25%). Discontinuation of ICI due to adverse events resulted in progressive disease (PD) in 71% of patients regardless of the initial response. A re-induction of ICI was initiated in 8 patients upon tumor progression. We observed a renewed tumor response in 4 of these 8 patients. Notably, all 4 patients showed an initial BOR of at least PR.
CONCLUSION
CONCLUSIONS
Our results from this contemporary cohort of patients with metastatic MCC indicate that MCC patients are at higher risk of relapse after discontinuation of ICI as compared to melanoma patients. Notably, the risk of disease progression after discontinuation of ICI treatment is lower in patients with initial CR (33%) as compared to patients with initial PR (66%) or SD (100%). Upon tumor progression, re-induction of ICI is a feasible option. Our data suggest that the BOR to initial ICI therapy might be a potential predictive clinical marker for a successful re-induction.
Identifiants
pubmed: 33870464
doi: 10.1007/s00262-021-02925-4
pii: 10.1007/s00262-021-02925-4
pmc: PMC8505278
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
3313-3322Informations de copyright
© 2021. The Author(s).
Références
Clin Cancer Res. 2013 Jan 15;19(2):462-8
pubmed: 23169436
Lancet Oncol. 2016 Oct;17(10):1374-1385
pubmed: 27592805
Nat Rev Dis Primers. 2017 Oct 26;3:17077
pubmed: 29072302
J Cancer Res Clin Oncol. 2019 Feb;145(2):511-521
pubmed: 30539281
Melanoma Res. 2017 Aug;27(4):321-325
pubmed: 28257394
Future Oncol. 2017 Aug;13(19):1699-1710
pubmed: 28605939
Clin J Oncol Nurs. 2019 Feb 1;23(1):E1-E9
pubmed: 30682006
Oncoimmunology. 2020 Jul 11;9(1):1792058
pubmed: 32923156
Am J Clin Dermatol. 2019 Jun;20(3):391-407
pubmed: 30784027
Dermatol Ther (Heidelb). 2019 Jun;9(2):209-222
pubmed: 30820877
J Immunother Cancer. 2018 Mar 23;6(1):23
pubmed: 29566749
J Clin Oncol. 2019 Mar 20;37(9):693-702
pubmed: 30726175
J Clin Oncol. 2017 Mar;35(7):785-792
pubmed: 28068177
J Clin Oncol. 2014 Apr 1;32(10):1020-30
pubmed: 24590637
Cancer Immunol Immunother. 2019 Apr;68(4):609-618
pubmed: 30721341
Eur J Cancer. 2018 Sep;101:160-164
pubmed: 30071444
Clin Cancer Res. 2018 May 1;24(9):2035-2043
pubmed: 29217527
Oncologist. 2019 Oct;24(10):1375-1383
pubmed: 30962295
Ann Oncol. 2019 Jul 1;30(7):1154-1161
pubmed: 30923820
J Clin Oncol. 2018 Jun 10;36(17):1668-1674
pubmed: 29283791